Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
NNC9204-1177 A/mL · 1 trial · 2 indications
Count of events
| Arm | Type | Description |
|---|---|---|
| NNC9204-1177 | EXPERIMENTAL | Dose trial with a sequential trial design |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| NNC9204-1177 A 1.0 mg/mL | DRUG | Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks. Dose gradually increased to 6000 μg. |
| PLACEBO | DRUG | Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks. |
Inclusion Criteria: * Male or female, aged 18-55 years (both inclusive) at the time of signing informed consent * Body mass index (BMI) between 27.0 and 39.9 kg/m2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator Exclusion Criteria: *...
NNC9204-1177 A/mL is an investigational small molecule drug developed by Novo Nordisk A/S for metabolism and nutrition disorders, including overweight and obesity. It has been studied in a Phase 1 clinical trial for weight management in people with overweight or obesity. It is not approved and remains in clinical development.
NNC9204-1177 A/mL has been studied for weight management in people with overweight or obesity, which falls under metabolism and nutrition disorders. The research has been conducted in Phase 1 clinical testing. It is an investigational therapy and has not been approved for any indication.
NNC9204-1177 A/mL is being developed by Novo Nordisk A/S, which trades under the ticker NVO. Novo Nordisk is the sponsor of the clinical research program for this investigational small molecule in metabolic disorders.
NNC9204-1177 A/mL is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not received FDA approval.
NNC9204-1177 A/mL has been evaluated in a single Phase 1 trial, NCT03308721, titled "Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity." The trial enrolled 99 participants, was randomized, double-blind, and placebo-controlled, and has been completed.